Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that the Pharmalot campus has quieted down. The shortest person has left for a new summer job overseeing even smaller people and the official mascots are enjoying snoozes under windows where cool breezes and a warm sunshine can be felt. As for us, we are quaffing cups of stimulation that sport a hint of Jack Daniel’s. As always, feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits. Hope you have a smashing day and please do keep in touch …

The House is touting passage of dozens of bills that could help combat the national opioid crisis, but a small handful of companies that have spent millions lobbying Congress could reap a windfall if any of the bills become law, Politico informs us. Among them is Alkermes (ALKS), which spent $1 million lobbying in part to support a bill to fund full-service centers where people can detox, receive medical care, and start treatment — a setup that could boost the fortunes of its best-selling product, anti-addiction treatment Vivitrol.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy